Scarica l'app Stockscreener
4.37
9.34%
-0.45
Dopo l'orario di chiusura:
4.46
0.09
+2.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.82
Aprire:
$4.98
Volume 24 ore:
25,618
Relative Volume:
0.25
Capitalizzazione di mercato:
$92.74M
Reddito:
$264.74M
Utile/perdita netta:
$-49.71M
Rapporto P/E:
-1.0669
EPS:
-4.0959
Flusso di cassa netto:
$-43.55M
1 W Prestazione:
-9.15%
1M Prestazione:
-4.59%
6M Prestazione:
+992.50%
1 anno Prestazione:
+70.70%
Intervallo 1D:
$4.28
$4.98
Intervallo di 1 settimana:
$4.22
$5.60
Portata 52W:
$0.3901
$12.30
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Nome
Camp 4 Therapeutics Corp
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CAMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.37 | 92.74M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | William Blair | Outperform |
| 2022-08-16 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2021-12-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2021-09-24 | Reiterato | Craig Hallum | Buy |
| 2021-06-25 | Reiterato | Craig Hallum | Buy |
| 2020-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-05 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-01 | Reiterato | Craig Hallum | Buy |
| 2019-03-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2018-12-14 | Reiterato | B. Riley FBR | Buy |
| 2018-12-11 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Iniziato | Goldman | Neutral |
| 2018-10-15 | Iniziato | Jefferies | Hold |
| 2018-09-28 | Reiterato | Craig Hallum | Hold |
| 2018-04-27 | Reiterato | Craig Hallum | Hold |
| 2018-03-08 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-02-16 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
Mostra tutto
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CAMP4 Therapeutics CEO to Present Corporate Update at J.P. Morgan Healthcare Conference - StockTitan
Strategic Investment Boosts Exploration Plans in Ontario's Gold Camp - Streetwise Reports
Camp4 Therapeutics sees MAD safety and key biomarker data in 2H25 - TipRanks
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones - The Manila Times
CAMP4 Therapeutics Advances Urea Cycle Disorder Drug After $82M IPO, Secures BioMarin Partnership - StockTitan
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - citybiz
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
CAMP4 Therapeutics to Present at Piper Sandler Healthcare Conference in NYC | CAMP Stock News - StockTitan
CAMP4 Reports Third Quarter 2024 Financial Results - The Manila Times
CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz
Camp4 Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CAMP4 Therapeutics Secures $370M BioMarin Deal, Raises $82M in IPO Milestone | CAMP Stock News - StockTitan
CalAmp Files Bankruptcy to Complete Debt Restructuring - MSN
Camp4 gains after earning bullish views on Street - MSN
Biopharma IPOs raise nearly $1B in October from 5 public debuts - BioWorld Online
William Blair Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
October IPOs in Biotech, Cleantech, Transportation, Retail and Homebuilder Sectors - Investorideas.com newswire
Camp4 Therapeutics initiated with an Overweight at Piper Sandler - MSN
JP Morgan Initiates Coverage of Camp4 Therapeutics (CAMP) with Overweight Recommendation - MSN
JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech - Investing.com Australia
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
Camp4 stock gains after earning bullish views (CAMP:NASDAQ) - Seeking Alpha
William Blair upbeat on CAMP4 shares with Outperform rating - Investing.com
William Blair upbeat on CAMP4 shares with Outperform rating By Investing.com - Investing.com Canada
Leerink sets stock target for CAMP4, cites broad UCD treatment potential - Investing.com India
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology - Investing.com
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Internet of Things (IoT) in Construction Market Worth Over $61.7 Billion by 2030Industry Analysis and Forecast with Profiles of 37 Major Companies Including Autodesk, Calamp Corp, Caterpillar, Dronedeploy - GlobeNewswire
(PDF) The Effectiveness of Incarceration‐Based Drug Treatment on Criminal Behavior: A Systematic Review - ResearchGate
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Camp4 Therapeutics sees $8.4 million stock purchase by Northpond Ventures - Investing.com India
Camp4 Therapeutics sees $7.99m stock purchase by investors By Investing.com - Investing.com India
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com India
CAMP4 Rings the Opening Bell - Nasdaq
Camp 4 Therapeutics Corp Azioni (CAMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Camp 4 Therapeutics Corp Azioni (CAMP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AH Equity Partners Bio I, L.L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
727,272 |
7,999,992 |
1,579,885 |
| Enavate Sciences GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
3,785,802 |
| Polaris Management Co. VII, L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| 5AM Partners VI, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Nashat Amir | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| Schwab Andrew J. | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Cohenour Jason | Director |
Jun 05 '24 |
Sale |
0.83 |
8,640 |
7,176 |
0 |
| Cohenour Jason | Director |
Mar 05 '24 |
Option Exercise |
0.00 |
7,824 |
0 |
10,962 |
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):